Hepatitis C vaccine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Hepatitis C vaccine" in English language version.

refsWebsite

Global rank English rank

9nih.gov

4^th place

6doi.org

2^nd place

1cdc.gov

218^th place

212^th place

1scripps.edu

low place

1web.archive.org

1^st place

1who.int

195^th place

302^nd place

1handle.net

102^nd place

76^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1ucl.ac.uk

1,306^th place

885^th place

1semanticscholar.org

11^th place

8^th place

cdc.gov

"Hepatitis C Questions and Answers for the Public". Centers for Disease Control and Prevention. 10 September 2019. Retrieved 20 April 2023.

clinicaltrials.gov

Clinical trial number NCT02772003 for "DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection" at ClinicalTrials.gov

doi.org

Randal J (June 1999). "Hepatitis C vaccine hampered by viral complexity, many technical restraints". Journal of the National Cancer Institute. 91 (11): 906–8. doi:10.1093/jnci/91.11.906. PMID 10359539.
Strickland GT, El-Kamary SS, Klenerman P, Nicosia A (June 2008). "Hepatitis C vaccine: supply and demand". The Lancet. Infectious Diseases. 8 (6): 379–86. doi:10.1016/S1473-3099(08)70126-9. PMID 18501853.
Torresi J (7 November 2017). "The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine". Frontiers in Microbiology. 8: 2163. doi:10.3389/fmicb.2017.02163. PMC 5674006. PMID 29163442.
Lombardi A, Mondelli MU (March 2019). "Hepatitis C: Is eradication possible?". Liver International. 39 (3): 416–426. doi:10.1111/liv.14011. hdl:2434/870308. PMID 30472772.
Latimer B, Toporovski R, Yan J, Pankhong P, Morrow MP, Khan AS, et al. (20 June 2014). "Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine". Human Vaccines & Immunotherapeutics. 10 (8): 2357–65. doi:10.4161/hv.29590. PMC 4896772. PMID 25424943.
Esposito I, Cicconi P, D'Alise AM, Brown A, Esposito M, Swadling L, et al. (June 2020). "MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans" (PDF). Science Translational Medicine. 12 (548): eaaz7715. doi:10.1126/scitranslmed.aaz7715. PMC 7610808. PMID 32554708. S2CID 219722045.

handle.net

hdl.handle.net

Lombardi A, Mondelli MU (March 2019). "Hepatitis C: Is eradication possible?". Liver International. 39 (3): 416–426. doi:10.1111/liv.14011. hdl:2434/870308. PMID 30472772.

nih.gov

pubmed.ncbi.nlm.nih.gov

Randal J (June 1999). "Hepatitis C vaccine hampered by viral complexity, many technical restraints". Journal of the National Cancer Institute. 91 (11): 906–8. doi:10.1093/jnci/91.11.906. PMID 10359539.
Strickland GT, El-Kamary SS, Klenerman P, Nicosia A (June 2008). "Hepatitis C vaccine: supply and demand". The Lancet. Infectious Diseases. 8 (6): 379–86. doi:10.1016/S1473-3099(08)70126-9. PMID 18501853.
Torresi J (7 November 2017). "The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine". Frontiers in Microbiology. 8: 2163. doi:10.3389/fmicb.2017.02163. PMC 5674006. PMID 29163442.
Lombardi A, Mondelli MU (March 2019). "Hepatitis C: Is eradication possible?". Liver International. 39 (3): 416–426. doi:10.1111/liv.14011. hdl:2434/870308. PMID 30472772.
Latimer B, Toporovski R, Yan J, Pankhong P, Morrow MP, Khan AS, et al. (20 June 2014). "Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine". Human Vaccines & Immunotherapeutics. 10 (8): 2357–65. doi:10.4161/hv.29590. PMC 4896772. PMID 25424943.
Esposito I, Cicconi P, D'Alise AM, Brown A, Esposito M, Swadling L, et al. (June 2020). "MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans" (PDF). Science Translational Medicine. 12 (548): eaaz7715. doi:10.1126/scitranslmed.aaz7715. PMC 7610808. PMID 32554708. S2CID 219722045.

ncbi.nlm.nih.gov

Torresi J (7 November 2017). "The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine". Frontiers in Microbiology. 8: 2163. doi:10.3389/fmicb.2017.02163. PMC 5674006. PMID 29163442.
Latimer B, Toporovski R, Yan J, Pankhong P, Morrow MP, Khan AS, et al. (20 June 2014). "Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine". Human Vaccines & Immunotherapeutics. 10 (8): 2357–65. doi:10.4161/hv.29590. PMC 4896772. PMID 25424943.
Esposito I, Cicconi P, D'Alise AM, Brown A, Esposito M, Swadling L, et al. (June 2020). "MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans" (PDF). Science Translational Medicine. 12 (548): eaaz7715. doi:10.1126/scitranslmed.aaz7715. PMC 7610808. PMID 32554708. S2CID 219722045.

scripps.edu

"Scripps Research Institute Scientists Achieve Most Detailed Picture Ever of Key Part of Hepatitis C Virus" (Press release). Scripps Research Institute. 28 November 2013. Retrieved 6 December 2013.

semanticscholar.org

api.semanticscholar.org

Esposito I, Cicconi P, D'Alise AM, Brown A, Esposito M, Swadling L, et al. (June 2020). "MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans" (PDF). Science Translational Medicine. 12 (548): eaaz7715. doi:10.1126/scitranslmed.aaz7715. PMC 7610808. PMID 32554708. S2CID 219722045.

ucl.ac.uk

discovery.ucl.ac.uk

Esposito I, Cicconi P, D'Alise AM, Brown A, Esposito M, Swadling L, et al. (June 2020). "MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans" (PDF). Science Translational Medicine. 12 (548): eaaz7715. doi:10.1126/scitranslmed.aaz7715. PMC 7610808. PMID 32554708. S2CID 219722045.

web.archive.org

"The hepatitis C virus". WHO. Archived from the original on 4 October 2013. Retrieved 1 October 2013.

who.int

"The hepatitis C virus". WHO. Archived from the original on 4 October 2013. Retrieved 1 October 2013.